SDC1 and Miyoshi myopathy: Regarding 5,6 β-EC, the decrease of CD138+ viability reached 59.2% and 48.2% for MM cells of patients P1 and P3, respectively, for a 40 μg/mL-treatment and remained almost constant for the highest dose of 80 μg/mL.